Benzinga | Jul 6, 2021 09:14AM EDT

ALX Oncology On Saturday Announced New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer

-- ORR of 72% Observed in Patients with >2L HER2 Positive Gastric or Gastroesophageal Junction Cancer

-- Estimated OS at 12 months of 76%

-- ALX Oncology to Host Conference Call on July 6th at 8:30 a.m. ET